ctDNA Liquid Biopsy Test - InVision First-Lung
ctDNA Liquid Biopsy Test

InVisionFirst®-Lung, a ctDNA NGS liquid biopsy testing 37 genes relevant to the care of patients with advanced NSCLC

Focused - 37 gene panel including NSCLC markers
Actionable - Largest prospective molecular diagnostics study in NSCLC published up to date in JCO Precision Oncology
Sensitive & Specific - Our technology brings high sensitivity and specificity to drive appropriate treatment choice
Timely Results - Results within 7 calendar days from blood draw

Covered for Medicare and other private insurance NSCLC patients who meet specific clinical criteria in the United States.

InVisionFirst-Lung® is available world-wide for both commercial and research use.

Focused - Support the prognosis and therapeutic decisions in patients diagnosed with NSCLC

37 gene panel including NSCLC markers

Supports the therapeutic decisions in patients diagnosed with advanced non-small cell lung cancer (NSCLC)

ALKBRAFEGFRERBB2 (HER2)RET
KRASMETROS1STK11NTRK1
VIEW FULL GENE LIST

Alterations associated with:
a) an FDA approved drug for another tumor type,
b) inclusion or exclusion criteria for clinical trials and/or,
c) indicators for resistance to therapy.

 

AKT1CCND1CDKN2ACTNNB1ESR1FGFR1FGFR2
FGFR3GATA3GNA11GNAQGNASHRASIDH1
IDH2KITMAP2K1MYCNFE2L2NRASNTRK3
PDGFRAPIK3CAPPP2R1APTENTP53U2AF1
SNVs + Indels - Hotspot Regions
Fusions + SNVs + Indels
CNVs + SNVs + Indels
Fusions
10 actionable genes relevant to advanced NSCLC  in a panel of 37 genes

  • ALK, BRAF, EGFR, NTRK1, RET, ROS1 for FDA-approved targeted therapies
  • MET and ERBB2 (HER2) as recommended by CAP/AMP/ASCO/IASLC guidelines
  • KRAS and STK11 for prognostic and therapeutic value as described in clinical literature
Actionable - 26% more actionable alterations  detected versus standard-of-care tissue testing

Largest prospective molecular diagnostics study in NSCLC published up to date in JCO Precision Oncology

98% concordance

observed with matched tissue profiling

InVisionFirst-Lung provided access to comprehensive genetic profiling (CGP) when tissue was not available

26% more actionable alterations

detected versus standard-of-care tissue testing

Sensitive & Specific - a detection range as low as 0.1% variant allele fraction with a mean read depth of 70,000.

Our technology brings high sensitivity and specificity to drive appropriate treatment choice

Liquid Biopsy detects SNVs, InDels, CNVs and SV

InVision® Platform can detect single nucleotide variants (SNVs), small insertions and deletions (InDels), copy number variant (CNVs), and structural variants (SV) such as fusions from plasma cell free DNA (cfDNA) with a detection range as low as 0.1% variant allele fraction with a mean read depth of 70,000.

Click here for InVisionFirst®-Lung clinical validation results and clinical utility data.

Timely Results - The report includes genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials

Results within 7 calendar days from blood draw

Sample InVisionFirst-Lung clinical report
  • Test results are delivered through a secure Clinician Portal
  • The report includes genetic alterations and corresponding recommended therapeutics, such as assessment of predicted response to treatments and available to currently enrolling clinical trials
  • This report can be easily exported and added to most electronic health records (EHRs)

InVisionFirst®-Lung can help at different stages:

At Diagnosis*

  • When results for EGFR single nucleotide variants (SNVs) and insertions and deletions (indels); rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAF are not available AND
  • When tissue-based CGP is infeasible (i.e. quantity not sufficient (QNS) for tissue-based CGP or invasive biopsy is medically contraindicated).

OR

At Progression*

  • For patients progressing on or after chemotherapy or immunotherapy who have not been tested for EGFR SNVs and indels; rearrangements in ALK, NTRK1, RET and ROS1; and SNVs for BRAFs, and for whom tissue-based CGP is infeasible; OR
  • For patients progressing on EGFR tyrosine kinase inhibitors (TKIs).

* If no genetic alteration is detected by InVisionFirst®-Lung or if circulating tumor DNA (ctDNA) is insufficient/not detected, tissue-based genotyping should be considered

Advocating for patients with advanced NSCLC

Inivata offers the InVision® Access Program, a supportive patient assistance program for eligible patients, to help at every step along the way.